tiprankstipranks
Adlai Nortye Ltd. Sponsored ADR (ANL)
NASDAQ:ANL
US Market

Adlai Nortye Ltd. Sponsored ADR (ANL) Price & Analysis

Compare
23 Followers

ANL Stock Chart & Stats


---

Bulls Say, Bears Say

Bulls Say
Clinical TrialsAN4005 delivers promising safety and preliminary efficacy with Phase 1 update.
Company StrategyAdlai Nortye has two important upcoming data catalysts, which should fuel positive investor sentiment and bolster the company's growing global footprint.
Market OpportunityThe small-molecule PD-L1 inhibitor space is underdeveloped with no drug approved, providing an opportunity for AN4005 to advance.
Bears Say
Clinical DevelopmentAN4005 is being investigated in an ongoing Phase 1, multi-center, open-label clinical trial study in patients with advanced solid tumors.
CompetitionThere are several oral small molecules PD-L1 candidates in early development stages, leaving the playing field open for AN4005 to advance.
Pipeline ChallengesThe broad, oncology-focused company portfolio is bolstered by strong external support through close collaborations with global partners.
---

Financials

Quarterly

Ownership Overview

0.05%99.95%
Insiders
Mutual Funds
0.05% Other Institutional Investors
99.95% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

ANL FAQ

What was Adlai Nortye Ltd. Sponsored ADR’s price range in the past 12 months?
Adlai Nortye Ltd. Sponsored ADR lowest stock price was $1.85 and its highest was $17.48 in the past 12 months.
    What is Adlai Nortye Ltd. Sponsored ADR’s market cap?
    Adlai Nortye Ltd. Sponsored ADR’s market cap is $81.18M.
      When is Adlai Nortye Ltd. Sponsored ADR’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Adlai Nortye Ltd. Sponsored ADR’s earnings last quarter?
      Adlai Nortye Ltd. Sponsored ADR released its earnings results on Aug 08, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$1.06 by $0.71.
        Is Adlai Nortye Ltd. Sponsored ADR overvalued?
        According to Wall Street analysts Adlai Nortye Ltd. Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Adlai Nortye Ltd. Sponsored ADR pay dividends?
          Adlai Nortye Ltd. Sponsored ADR does not currently pay dividends.
          What is Adlai Nortye Ltd. Sponsored ADR’s EPS estimate?
          Adlai Nortye Ltd. Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Adlai Nortye Ltd. Sponsored ADR have?
          Adlai Nortye Ltd. Sponsored ADR has 93,710,810 shares outstanding.
            What happened to Adlai Nortye Ltd. Sponsored ADR’s price movement after its last earnings report?
            Adlai Nortye Ltd. Sponsored ADR reported an EPS of -$0.35 in its last earnings report, beating expectations of -$1.06. Following the earnings report the stock price went up 3.974%.
              Which hedge fund is a major shareholder of Adlai Nortye Ltd. Sponsored ADR?
              Currently, no hedge funds are holding shares in ANL
              ---

              ANL Stock 12 Month Forecast

              Average Price Target

              $9.00
              ▲(307.24% Upside)
              {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","14":"$14","4.25":"$4.25","7.5":"$7.5","10.75":"$10.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4.25,7.5,10.75,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Sep<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,3.166153846153846,3.6523076923076925,4.138461538461539,4.624615384615385,5.110769230769231,5.596923076923077,6.0830769230769235,6.569230769230769,7.055384615384616,7.541538461538462,8.027692307692307,8.513846153846155,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,3.166153846153846,3.6523076923076925,4.138461538461539,4.624615384615385,5.110769230769231,5.596923076923077,6.0830769230769235,6.569230769230769,7.055384615384616,7.541538461538462,8.027692307692307,8.513846153846155,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,3.166153846153846,3.6523076923076925,4.138461538461539,4.624615384615385,5.110769230769231,5.596923076923077,6.0830769230769235,6.569230769230769,7.055384615384616,7.541538461538462,8.027692307692307,8.513846153846155,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.1,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.1,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.1,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.1,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.1,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.1,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.1,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.1,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.1,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
              Similar Stocks
              Company
              Price & Change
              Follow
              Incyte
              Fate Therapeutics
              Adaptimmune Therapeutics
              BeiGene
              Immatics

              Best Analysts Covering ANL

              1 Year
              Joseph PantginisH.C. Wainwright
              1 Year Success Rate
              1/3 ratings generated profit
              33%
              1 Year Average Return
              -14.47%
              reiterated a buy rating 3 months ago
              Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -14.47% per trade.
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis